The Food and Drug Administration approved Revolution Medicines' promising pancreatic cancer drug on Aug. 26 after a clinical trial showed life expectancy nearly doubled for patients with disease that ...

A pill that doubles life expectancy in patients with pancreatic cancer has been hailed as the biggest breakthrough for decades. Doctors are billing daraxonrasib as a “revolution” in cancer treatment, ...

Patients taking the drug nearly doubled their survival time, with fewer severe side effects.

Thunderous applause at this year’s American Society for Clinical Oncology (ASCO) meeting in May — hardly the typical reaction ...

Patients most likely to benefit from the blood test include those with a higher genetic risk, a family history of pancreatic ...

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be harnessed for cancer therapy. Given that more than 95% of pancreatic ductal ...

Yet I kept dragging my feet, in part because it was less painful to ignore the danger. Over time I would put aside my ...